Pharmacological administration of granulocyte/macrophage-colony- stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

Cancer Immunology Immunotherapy

Volumn 47, Issue 3, 1998, Pages 131-142

  Samanci, Ali ^a   Yi, Qing ^a   Fagerberg, Jan ^a   Strigård, Karin ^a   Smith, Gale ^e   Rüden, Ulla ^b   Wahren, Britta ^c   Mellstedt, Håkan ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e Protein Sciences Corp   (United States)

Author keywords

GM CSF; Immune response; rCEA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INTERFERON PRODUCTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0031771557     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050513     Document Type: Article

References (49)

1. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H (1995) Anti-tumor effect induced by GM-CSF gene modified tumor vaccination: comparison of adenovirus-and retrovirus mediated genetic transduction. J Cancer Res Clin Oncol 121:587
2. Conry RM, Salah MN, Schlom J, LoBuglio AF (1995) Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man (abstract). Proc Am Assoc Cancer Res Annu Meet 36:492
3. DiGiorgio A, Botti C, Tocchi A, Mingazzini P, Flammia M (1992) The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients, Int Surg 77:256
4. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202
5. Dranoff G, Jaffee E, Lazenby A, Golumbek P Levitsky H Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
6. Fagerberg J, Steinitz M, Wigzell H, Askelöf P, Mellstedt H (1995) Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92:4773
7. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm A-L, Mellstedt H, Frödin J-E (1996) Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 42:81
8. Fagerberg J, Samanci A, Strigård K, Rudén U, Mellstedt H (1997) Induction of specific T cells after immunization with baculovirus produced recombinant tumor associated antisens - mapping of T cell epitopes (abstract). J Immunother 20:417
9. Fairchild PJ, Wraith DC (1996) Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 17:80
10. Golumbek PT, Azari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM (1993) Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53:5841
11. - T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp Med 161:1122
12. Hamilton Jm, Chen AP, Nguyen B, Grem J, Abrams S, Chung Y, Kantor J, Phares JC, Bastian A, Brooks C, Morrison G, Allegra CJ, Schlom J (1994) Phase 1 study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas (abstract). Proc Am Soc Clin Oncol Annu Meet 13:961
13. Hammarström S, Engvull E, Johansson BG, Svensson S. Sundhlad G, Goldstein IJ (1975) Nature of the tumor-associated determinanl(s) of carcinoembryonic antigen. Proc Natl Acad Sci USA 72:1528
14. Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390
15. Hsieh J-T, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH (1995) Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55:190
16. Jäger E. Ringhoffer M, Dienes HP, Arand M, Karbach J, Jäger D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associtated peptides in vivo, Int J Cancer 67:54
17. Kabilan L, Troye-Blomberg M, Perlmann H, Andersson G, Högh B, Petersen E, Björkman A, Perlmann P (1998) T cell epitopes in Pf155 RESA, a major candidate for a plasmodium falciparum malaria vaccine. Proc Natl Acad Sci USA 85:5659
18. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J (1992) Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 84:1084
19. Krupey J, Wilson T, Freedman SO, Gold P (1972) The preparation of purified carcinoembryonic antigen of the human digestive system from large quantities of tumor time. Immunochemistry 9:617
20. Kwak LW, Young HA, Penmngton RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972
21. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll' K, Guarnieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858
22. Lin K-Y, Guarnieri FG, Stavelev-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibilily class II presentation of tumor antigen. Cancer Res 56:21
23. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685
24. Loihner H, Janzek E, Mayor P, Liehl E (1995) Vaccination of rhesus monkeys with an anti-idiotype antibody mimicking Lewis Y: enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF (abstract). Antibody Immunoconjugates Radiopharm 8:64
25. Longenecker BM, MacLean G (1993) Prospects for mucin epitopes in cancer vaccines. Immunologist 1:89-93
26. Lopez-Nevot MA, Esteban F, Perron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F, Garrido F (1989) HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221
27. Mzabi R, Himal HS, Demers R, MacLean LD (1976) A multiparametric computer analysis of carcinoma of the colon. Surg Gynecol Obstet 143:959
28. O'Connell MJ, Laurie JA, Shepherd L, et al (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group (abstract). Proc Am Soc Clin Oncol Annu Meet 15:478
29. Oikawa S, Nakazato H, Kosaki G (1987) Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. Biochem Biophys Res Commun 142:511
30. Paglia P, Chiodoni C, Rodolfo M (1996) Murine dendritic cells loaded in vitro with soluble protein cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317
31. Pantel K, Izhicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmüller G (1996) Frequency and prognostic significance of isolated tumour cells in hone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347:649
32. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of the monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long lasting, complete remissions can be induced. Int J Cancer 53:751
33. Ragnhammar P, Frödin J-E, Hjelm A-L, Fagerberg J, Wersäll P, Lindemalm C, Nilsson B, Fox K, Magnusson I, Ewerth S, Thor K, Secher E, Mellstedt H (1995) Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma. Int J Oncol 7:1049
34. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, the German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 343:1177
35. Rock KL (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131
36. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109
37. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacker V (1992) Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol Immunother 35:325
38. Schrewe H, Thompson J, Bona M, Hefta LJ, Maruya A, Hassauer M, Shively JE, von Kleist S, Zimmermann W (1990) Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 10:2738
39. Somasundarum R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 155:3253
40. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G, Ivany H (1994) Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81:171
41. Svanholm C, Löwenadler B, Wigzell H (1997) Amplification of T-cell and antibody responses in DNA-based immunization with HIV-1 Nef by co-injection with a GM-CSF expression vector. Scand J Immunol 46:298
42. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaume M, Jones TC (1996) Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 14:1199
43. Thompson JA, Grunert F, Zimmerman W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344
44. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461
45. Tsang KY, Zaremba S, Nieroda CA, Zhu ZM, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patient immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982
46. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirukawa K, Hamada H (1996) Intensified antitumor immunity by a cancer vaccine that produces granulocyle-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:1828
47. Vermorken JB, Claessen A, Gall H, Holtev A van, Tinteren H van, Meijr S, Steffelaar H, Brakenhoff J, Bochove A van, Scheper R, Meijer C, Hanna M, Pinedo H (1997) Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes' B2, B3 and C colon cancer (abstract). European Conference on Clinical Oncology (ECCO) 9:S162
48. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM (1987) Granulocyte macrophage colony-stimulating factor is essential for the viability and function of cultured niurine epidermal Langerhans cells. J Exp Med 166:1484
49. Österborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Rudén U, Lefvert A-K, Holm G, Mellstedt H (1998) Idiotype immunization combined with GM-CSK in myeloma patients induced type I, MHC-restricted, CD8 and CD4 specific T cell responses. Blood 91:1-9